Gabather AB (publ)
Research Gabather AB (publ) (GABA) on Bullrun: market cap SEK 18.80M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGABA
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencySEK
- Market capSEK 18.80M
- Financial periodQ1 2026
- RevenueSEK 0
- Net income-SEK 1.07M
- Free cash flow-SEK 331.00K
Valuation Snapshot
latest market cap is SEK 18.80M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 0 | -SEK 4.56M | -SEK 7.21M | n/a | -0.03 | SEK 3.14M | n/a | SEK 662.00K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | SEK 18.80M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Gabather AB (publ)
Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. The company focuses on developing GT-002, a pro-cognitive drug candidate for the treatment of Alzheimer's disease, schizophrenia, and major depressive disorders.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Gabather AB (publ)'s market cap?
Gabather AB (publ)'s market capitalization is SEK 18.80M.
What does Gabather AB (publ) do?
Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. The company focuses on developing GT-002, a pro-cognitive drug candidate for the treatment of Alzheimer's disease, schizophrenia, and major depressive disorders. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje, Sweden.